Brokerages expect COLLPLANT HOLDI/S (NASDAQ:CLGN) to post earnings per share (EPS) of ($0.41) for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for COLLPLANT HOLDI/S’s earnings. COLLPLANT HOLDI/S reported earnings per share of ($0.50) during the same quarter last year, which would suggest a positive year-over-year growth rate of 18%. The firm is expected to announce its next earnings report on Thursday, May 23rd.
According to Zacks, analysts expect that COLLPLANT HOLDI/S will report full-year earnings of ($1.62) per share for the current financial year. For the next year, analysts expect that the company will post earnings of ($1.22) per share. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that that provide coverage for COLLPLANT HOLDI/S.
COLLPLANT HOLDI/S (NASDAQ:CLGN) last announced its quarterly earnings data on Monday, April 1st. The company reported $0.20 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.54) by $0.74. The company had revenue of $4.21 million during the quarter, compared to the consensus estimate of $19.35 million. COLLPLANT HOLDI/S had a negative return on equity of 3.27% and a negative net margin of 24.19%.
CLGN stock traded down $0.10 during midday trading on Wednesday, hitting $5.00. The company’s stock had a trading volume of 2,120 shares, compared to its average volume of 4,449. COLLPLANT HOLDI/S has a 12 month low of $3.13 and a 12 month high of $8.73. The company has a market capitalization of $19.84 million, a price-to-earnings ratio of -9.09 and a beta of 2.19.
COLLPLANT HOLDI/S Company Profile
CollPlant Holdings Ltd., a regenerative medicine company, focuses on developing and commercializing tissue repair products for three-dimensional (3D) bio-printing of tissues and organs, dermal fillers for aesthetics, orthobiologics, and advanced wound care markets in the United States, Canada, and Europe.
Recommended Story: What does a market perform rating mean?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for COLLPLANT HOLDI/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for COLLPLANT HOLDI/S and related companies with MarketBeat.com's FREE daily email newsletter.